Date: 2017-03-23
Type of information: Clinical research agreement
Compound: ICT-107, ICT-140 and ISF35
Company: ImmunoCellular Therapeutics (USA - CA) Memgen (USA - TX
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: immunotherapy product/cell therapy
Disease:
Details: * On March 23, 2017, ImmunoCellular Therapeutics and Memgen announce the signing of a non-binding letter of intent to exclusively negotiate the terms to possibly establish an immuno-oncology strategic collaboration focused on conducting clinical trials combining the companies' respective cancer immunotherapy product candidates. The discussions pertain to ImmunoCellular's dendritic cell (DC)-based immunotherapy product candidates, ICT-107 and ICT-140, and Memgen's ISF35, a viral cancer immunotherapy encoding an optimized version of CD40 ligand. Combining DC-based and viral oncology immunotherapeutic approaches could provide a novel way to stimulate CD40 to possibly induce a potent, specific and effective anti-tumor response. Insights from these combination trials, if successful, could also lead to later combination trials with other immune-oncology technologies, including checkpoint inhibitors. Preclinical research presented at the 2016 American Association of Cancer Research (AACR) Annual Meeting showed that ISF35 in combination with checkpoint inhibitors induces anti-tumor immune responses, expands tumor specific CD8 T cells, and has the potential to eradicate brain tumors. The combination of ISF35 and ICT-107 with checkpoint inhibitors may provide a multi-pronged antitumor immune response. This includes ISF35's CD40-driven dendritic and T cell activation and expansion, ICT-107's tumor-specific antigen presentation, and checkpoint inhibitor release of the PD-1 pathway-mediated inhibition of the antitumor immune response. If the parties agree upon the terms of a strategic collaboration, including financials, development, supply and control, ImmunoCellular and Memgen plan to work together to determine the best clinical strategy to leverage the collaboration.
Financial terms:
Latest news: